Use of FGF21 analogs for the treatment of metabolic disorders: a systematic review and meta-analysis
Arch. endocrinol. metab. (Online)
; 68: e220493, 2024. tab, graf
Article
в En
|
LILACS-Express
| LILACS
| ID: biblio-1520080
Ответственная библиотека:
BR1.1
ABSTRACT
ABSTRACT FGF21 is a hormone produced primarily by the liver with several metabolic functions, such as induction of heat production, control of glucose homeostasis, and regulation of blood lipid levels. Due to these actions, several laboratories have developed FGF21 analogs to treat patients with metabolic disorders such as obesity and diabetes. Here, we performed a systematic review and meta-analysis of randomized controlled trials that used FGF21 analogs and analyzed metabolic outcomes. Our search yielded 236 articles, and we included eight randomized clinical trials in the meta-analysis. The use of FGF21 analogs exhibited no effect on fasting blood glucose, glycated hemoglobin, HOMA index, blood free fatty acids or systolic blood pressure. However, the treatment significantly reduced fasting insulinemia, body weight and total cholesterolemia. None of the included studies were at high risk of bias. The quality of the evidence ranged from moderate to very low, especially due to imprecision and indirection issues. These results indicate that FGF21 analogs can potentially treat metabolic syndrome. However, more clinical trials are needed to increase the quality of evidence and confirm the effects seen thus far.
Полный текст:
1
База данных:
LILACS
Тип исследования:
Systematic_reviews
Язык:
En
Журнал:
Arch Endocrinol Metab
/
Arch. endocrinol. metab. (Online)
/
Archives of endocrinology and metabolism (Impresso)
/
Archives of endocrinology and metabolism (Online)
Тематика журнала:
ENDOCRINOLOGIA
/
METABOLISMO
Год:
2024
Тип:
Article